Similar Effectiveness, Safety of Biosimilar CT-P6 vs Reference Trastuzumab in Retrospective Study
June 13th 2022An analysis of retrospective data demonstrated comparable safety and efficacy profiles between CT-P6, a trastuzumab biosimilar, and Herceptin (reference trastuzumab) combined with chemotherapy and pertuzumab.
Ryan Haumschild, PharmD, Advises Practices, Health Systems to Prep for Interchangeable Biosimilars
June 5th 2022Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, gives an overview of what practices and health systems need to prepare for as more interchangeable biosimilars enter the US market.
Biosimilar Policy Roundup: May 2022
May 31st 2022May brought a number of biosimilar policy updates of all types, including updates on British Columbia's switching program, a new bill that could revamp biosimilar user fee programs, and insight into how companies are shaping their environmental policies around biosimilars.
Julie Reed Catalogues Actions Needed to Ensure Biosimilars Benefit Patients
May 29th 2022Combatting misinformation surrounding interchangeability and incentivizing biosimilars are just some of the many things that can be done to ensure patients benefit from biosimilars savings, said Julie M. Reed, the executive director of the Biosimilars Forum.
Dr Sonia Oskouei Predicts How Bevacizumab Use Will Evolve in Ophthalmology
May 22nd 2022The use of bevacizumab products for ophthalmic conditions will continue to evolve as the market grows. However, off-label usage will likely be the norm, according to Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health, at Asembia’s Specialty Pharmacy Summit.
Eye on Pharma: Similis Bio Launch, Biocon Biologics Sets Sights on Malaysian Biosimilar Market
May 19th 2022New biosimilars are on the way, as JSR Life Sciences launches its business division (Similis Bio) that will improve efficiency and costs related to biosimilar development and Biocon Biologics signs a contract for commercialization in Malaysia.
Dr Eric Tichy Calls for Government Officials to Realign Incentives in Favor of Biosimilars
May 18th 2022Altering reimbursement procedures needs to become a bigger priority for government officials to incentivize biosimilar utilization, according to Eric Tichy, PharmD, MBA, vice chair of pharmacy formulary at the Mayo Clinic Health System.
Contributor: No Good Deed Goes Unpunished—How PBM Mandates Increase Practice Variability
May 17th 2022Jeff Patton, MD, CEO and board member at OneOncology, dived into the controversial role that pharmacy benefit managers (PBMs) play in formulary decision-making and how PBMs impact biosimilar utilization.